Share on StockTwits

bluebird bio (NASDAQ:BLUE) COO Jeffrey T. Walsh unloaded 6,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $24.23, for a total transaction of $145,380.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of bluebird bio (NASDAQ:BLUE) traded up 0.44% during mid-day trading on Thursday, hitting $25.27. 87,626 shares of the company’s stock traded hands. bluebird bio has a 1-year low of $17.03 and a 1-year high of $36.25. The stock has a 50-day moving average of $21.94 and a 200-day moving average of $22.31. The company’s market cap is $619.4 million.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. On average, analysts predict that bluebird bio will post $-1.79 earnings per share for the current fiscal year.

Separately, analysts at Zacks upgraded shares of bluebird bio from an “underperform” rating to a “neutral” rating in a research note on Wednesday, May 14th. They now have a $19.90 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. bluebird bio has a consensus rating of “Buy” and an average price target of $37.73.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.